{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"363"}],"units":"Participants"}],"groups":[{"description":"Patients received 6 or 8 21-day cycles of CHOP (cyclophosphamide, hydroxydaunorubicin \\[doxorubicin\\], Oncovin \\[vincristine\\], prednisone) or CVP (cyclophosphamide, vincristine, prednisone) in combination with rituximab 375 mg/m\\^2 administered by intravenous (IV) infusion on Day 1 of each cycle.","id":"OG000","title":"Rituximab 375 mg/m^2"}],"paramType":"NUMBER","populationDescription":"Per-protocol evaluable population: All patients who received rituximab by faster infusion in Cycle 2 and who did not experience a Grade 3 or 4 infusion-related reaction during the rituximab infusion given at the standard rate during Cycle 1.","reportingStatus":"POSTED","timeFrame":"Cycle 2 through Cycle 6 or 8 (end of study)","title":"Percentage of Patients Who Had an Adverse Event of Any Grade or Seriousness During Cycle 2 Through Cycle 6 or 8 (End of Study)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}